Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.
The Health Resources and Services Administration, an HHS agency, reported that 340B covered entities purchased $81.4 billion in outpatient drugs through the 340B program in 2024. Disproportionate share hospitals spent about $64.13 billion, children’s hospitals $2.37 billion, critical access hospitals $1.19 billion, sole community hospitals $549 million, and freestanding cancer centers $602 million.
About 31% of the $81.4 billion was spent on 10 medications, according to the report.
The brand names of the 10 drugs with the highest expenditures in the 340B program last year were:
1. Keytruda (oncology) — $8.16 billion
2. Biktarvy (HIV) — $4.2 billion
3. Darzalex Faspro (oncology) — $2.46 billion
4. Opdivo (oncology) — $2.15 billion
5. Trikafta (cystic fibrosis) — $2.07 billion
6. Ocrevus (multiple sclerosis) — $1.97 billion
7. Descovy (HIV) — $1.18 billion
8. Stelara (immunology) — $1.11 billion
9. Imfinzi (oncology) — $1.09 billion
10. Entyvio (immunology) — $968 million
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
